| Literature DB >> 31974566 |
Eudocia Q Lee1,2, Michael Weller3, Joohee Sul4, Stephen J Bagley5, Solmaz Sahebjam6, Martin van den Bent7, Manmeet Ahluwalia8, Jian L Campian9, Evanthia Galanis10, Mark R Gilbert11, Matthias Holdhoff12, Glenn J Lesser13, Frank S Lieberman14, Minesh P Mehta15, Marta Penas-Prado11, Karisa C Schreck12, Roy E Strowd13, Michael A Vogelbaum6, Tobias Walbert16, Susan M Chang17, L Burt Nabors18, Stuart Grossman12, David A Reardon1,2, Patrick Y Wen1,2.
Abstract
Building on an initiative to enhance clinical trial participation involving the Society for Neuro-Oncology, the Response Assessment in Neuro-Oncology Working Group, patient advocacy groups, clinical trial cooperative groups, and other partners, we evaluate the impact of eligibility criteria and trial conduct on neuro-oncology clinical trial participation. Clinical trials often carry forward eligibility criteria from prior studies that may be overly restrictive and unnecessary and needlessly limit patient accrual. Inclusion and exclusion criteria should be evaluated based on the goals and design of the study and whether they impact patient safety and/or treatment efficacy. In addition, we evaluate clinical trial conduct as a barrier to accrual and discuss strategies to minimize such barriers for neuro-oncology trials.Entities:
Keywords: clinical trials; eligibility; exclusion criteria; inclusion criteria; primary brain tumor
Mesh:
Year: 2020 PMID: 31974566 PMCID: PMC7229255 DOI: 10.1093/neuonc/noaa015
Source DB: PubMed Journal: Neuro Oncol ISSN: 1522-8517 Impact factor: 12.300